Evercore ISI downgraded Dentsply Sirona (XRAY) to In Line from Outperform with a $20 price target The firm is moving to the sidelines as it awaits a more visible path toward a return to market growth given the continuity of Byte still to be determined, a “somewhat sluggish” implant and equipment turnaround story and the German tax overhang, the analyst tells investors. The firm assumes Byte remains suspended and sees about flat implant organic growth in FY25, the analyst added.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XRAY:
- Dentsply Sirona price target lowered to $23 from $30 at Morgan Stanley
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- Dentsply Sirona initiated with a Neutral at Mizuho
- Patterson Companies initiated with a Neutral at Mizuho
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
